Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen's 'Underappreciated' Inflammation Portfolio Set to Trigger Growth, RBC Capital Analyst Says

10/05/2021 | 03:26pm EST


ę MT Newswires 2021
All news about AMGEN INC.
12/01Amgen Arthritis Drug Shows Promise as Psoriasis Medication During Phase III Testing
MT
12/01Amgen Announces Positive Top-Line Results From Otezla« (apremilast) Phase 3 DISCREET St..
PR
12/01Amgen Inc. Announces Positive Top-Line Results From Otezla? Phase 3 DISCREET Study In M..
CI
12/01Johnson & Johnson's Janssen Lands FDA Nod for Multiple Myeloma Treatment
MT
12/01Amgen Gets FDA Nod for New Kyprolis Combo Regimen for Multiple Myeloma
MT
12/01Amgen Says FDA Approves Kyprolis Combination to Treat Multiple Myeloma
DJ
11/29AMGEN : Every Patient Counts, Every Story Matters
PU
11/29Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year
PR
11/29BRISTOL-MYERS SQUIBB : Deucravacitinib Applications Advance in U.S., Europe
DJ
11/24Amgen To Present At The 2021 Evercore ISI Healthcare Conference
PR
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 018 M - -
Net income 2021 5 551 M - -
Net Debt 2021 22 411 M - -
P/E ratio 2021 20,3x
Yield 2021 3,47%
Capitalization 113 B 113 B -
EV / Sales 2021 5,21x
EV / Sales 2022 4,88x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 200,80 $
Average target price 238,86 $
Spread / Average Target 19,0%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-13.50%113 104
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ELI LILLY AND COMPANY47.55%225 859